Neuren Pharmaceuticals Says Daybue Year-to-Date Net Sales Exceeds $250 Million Full-Year Threshold; Shares Up 7%

MT Newswires Live11-07

Neuren Pharmaceuticals (ASX:NEU) said net sales of oral Rett syndrome treatment Daybue from January to September exceeded the full-year threshold of $250 million for the company to earn the first sales milestone income of $50 million, according to a Thursday filing with the Australian bourse.

The company's royalties from partner Acadia Pharmaceuticals increased to AU$13.2 million in the third quarter, bringing the cumulative royalties for the year to AU$37.5 million, the filing said.

The company estimates fourth quarter royalties to be between AU$16 million and AU$18 million.

Additionally, the company anticipates a total income of AU$216 million to AU$218 million for 2024, including royalties, sales milestone payment, the share of the Rare Pediatric Disease Priority Review Voucher proceeds from Acadia Pharmaceuticals' sale, and AU$11m in interest income, according to the filing.

Neuren Pharmaceuticals shares rose nearly 7% in afternoon trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481399725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 10:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481399725","market":"fut","top_or_hot":-1,"title":"Neuren Pharmaceuticals Says Daybue Year-to-Date Net Sales Exceeds $250 Million Full-Year Threshold; Shares Up 7%","media":"MT Newswires Live","content":"<html><body><p> Neuren Pharmaceuticals (ASX:NEU) said net sales of oral Rett syndrome treatment Daybue from January to September exceeded the full-year threshold of $250 million for the company to earn the first sales milestone income of $50 million, according to a Thursday filing with the Australian bourse.</p><p>The company's royalties from partner Acadia Pharmaceuticals increased to AU$13.2 million in the third quarter, bringing the cumulative royalties for the year to AU$37.5 million, the filing said.</p><p>The company estimates fourth quarter royalties to be between AU$16 million and AU$18 million.</p><p>Additionally, the company anticipates a total income of AU$216 million to AU$218 million for 2024, including royalties, sales milestone payment, the share of the Rare Pediatric Disease Priority Review Voucher proceeds from Acadia Pharmaceuticals' sale, and AU$11m in interest income, according to the filing.</p><p>Neuren Pharmaceuticals shares rose nearly 7% in afternoon trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals Says Daybue Year-to-Date Net Sales Exceeds $250 Million Full-Year Threshold; Shares Up 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals Says Daybue Year-to-Date Net Sales Exceeds $250 Million Full-Year Threshold; Shares Up 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neuren Pharmaceuticals (ASX:NEU) said net sales of oral Rett syndrome treatment Daybue from January to September exceeded the full-year threshold of $250 million for the company to earn the first ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481399725","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481399725","pubTimestamp":1730946310,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals (ASX:NEU) said net sales of oral Rett syndrome treatment Daybue from January to September exceeded the full-year threshold of $250 million for the company to earn the first sale","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD"},"translate_title":"Neuren Pharmaceuticals表示，Daybue今年迄今的净销售额超过了2.5亿美元的全年门槛；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":0.9},"content_text":"Neuren Pharmaceuticals (ASX:NEU) said net sales of oral Rett syndrome treatment Daybue from January to September exceeded the full-year threshold of $250 million for the company to earn the first sales milestone income of $50 million, according to a Thursday filing with the Australian bourse.The company's royalties from partner Acadia Pharmaceuticals increased to AU$13.2 million in the third quarter, bringing the cumulative royalties for the year to AU$37.5 million, the filing said.The company estimates fourth quarter royalties to be between AU$16 million and AU$18 million.Additionally, the company anticipates a total income of AU$216 million to AU$218 million for 2024, including royalties, sales milestone payment, the share of the Rare Pediatric Disease Priority Review Voucher proceeds from Acadia Pharmaceuticals' sale, and AU$11m in interest income, according to the filing.Neuren Pharmaceuticals shares rose nearly 7% in afternoon trade.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481399725"}